> top > docs > PubMed:26685104 > annotations

PubMed:26685104 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 128-382 DRI_Background denotes Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery.
T2 383-532 DRI_Challenge denotes The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction.
T3 533-703 DRI_Approach denotes We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia.
T4 704-1036 DRI_Background denotes PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation.
T5 1037-1217 DRI_Challenge denotes We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation.
T6 1218-1566 DRI_Background denotes Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3: 144 to 111 mmHg and TLR7: 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3: 5.68 to 3.72 and TLR7: 5.57 to 3.84; both p<0.05).
T7 1567-1810 DRI_Background denotes Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3: 35 to 65% and TLR7: 37 to 63%; both p<0.05).
T8 1811-1978 DRI_Background denotes Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells.
T9 1979-2089 DRI_Background denotes Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses.
T10 2090-2266 DRI_Outcome denotes These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment.

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-127 Sentence denotes Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice.
TextSentencer_T2 128-382 Sentence denotes Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery.
TextSentencer_T3 383-532 Sentence denotes The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction.
TextSentencer_T4 533-703 Sentence denotes We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia.
TextSentencer_T5 704-1036 Sentence denotes PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation.
TextSentencer_T6 1037-1217 Sentence denotes We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation.
TextSentencer_T7 1218-1382 Sentence denotes Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3:
TextSentencer_T8 1383-1408 Sentence denotes 144 to 111 mmHg and TLR7:
TextSentencer_T9 1409-1515 Sentence denotes 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3:
TextSentencer_T10 1516-1538 Sentence denotes 5.68 to 3.72 and TLR7:
TextSentencer_T11 1539-1566 Sentence denotes 5.57 to 3.84; both p<0.05).
TextSentencer_T12 1567-1765 Sentence denotes Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3:
TextSentencer_T13 1766-1785 Sentence denotes 35 to 65% and TLR7:
TextSentencer_T14 1786-1810 Sentence denotes 37 to 63%; both p<0.05).
TextSentencer_T15 1811-1978 Sentence denotes Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells.
TextSentencer_T16 1979-2089 Sentence denotes Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses.
TextSentencer_T17 2090-2266 Sentence denotes These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment.
T1 0-127 Sentence denotes Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice.
T2 128-382 Sentence denotes Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery.
T3 383-532 Sentence denotes The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction.
T4 533-703 Sentence denotes We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia.
T5 704-1036 Sentence denotes PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation.
T6 1037-1217 Sentence denotes We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation.
T7 1218-1382 Sentence denotes Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3:
T8 1383-1408 Sentence denotes 144 to 111 mmHg and TLR7:
T9 1409-1515 Sentence denotes 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3:
T10 1516-1538 Sentence denotes 5.68 to 3.72 and TLR7:
T11 1539-1566 Sentence denotes 5.57 to 3.84; both p<0.05).
T12 1567-1765 Sentence denotes Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3:
T13 1766-1785 Sentence denotes 35 to 65% and TLR7:
T14 1786-1810 Sentence denotes 37 to 63%; both p<0.05).
T15 1811-1978 Sentence denotes Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells.
T16 1979-2089 Sentence denotes Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses.
T17 2090-2266 Sentence denotes These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment.

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-127 Sentence denotes Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice.
T2 128-382 Sentence denotes Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery.
T3 383-532 Sentence denotes The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction.
T4 533-703 Sentence denotes We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia.
T5 704-1036 Sentence denotes PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation.
T6 1037-1217 Sentence denotes We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation.
T7 1218-1382 Sentence denotes Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3:
T8 1383-1408 Sentence denotes 144 to 111 mmHg and TLR7:
T9 1409-1515 Sentence denotes 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3:
T10 1516-1538 Sentence denotes 5.68 to 3.72 and TLR7:
T11 1539-1566 Sentence denotes 5.57 to 3.84; both p<0.05).
T12 1567-1765 Sentence denotes Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3:
T13 1766-1785 Sentence denotes 35 to 65% and TLR7:
T14 1786-1810 Sentence denotes 37 to 63%; both p<0.05).
T15 1811-1978 Sentence denotes Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells.
T16 1979-2089 Sentence denotes Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses.
T17 2090-2266 Sentence denotes These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment.
T1 0-127 Sentence denotes Human placenta-derived stromal cells decrease inflammation, placental injury, and blood pressure in hypertensive pregnant mice.
T2 128-382 Sentence denotes Preeclampsia, the development of hypertension and proteinuria or end-organ damage during pregnancy, is a leading cause of both maternal and fetal morbidity and mortality and there are no effective clinical treatments for preeclampsia aside from delivery.
T3 383-532 Sentence denotes The development of preeclampsia is characterized by maladaptation of the maternal immune system, excessive inflammation, and endothelial dysfunction.
T4 533-703 Sentence denotes We have reported that detection of extracellular RNA by Toll-like receptors (TLRs) 3 and 7 is a key initiating signal that contributes to the development of preeclampsia.
T5 704-1036 Sentence denotes PLacental eXpanded (PLX-PAD; Pluristem Therapeutics, Inc., Haifa, Israel) cells are human placenta-derived, mesenchymal-like adherent stromal cells that have anti-inflammatory, pro-angiogenic, cytoprotective, and regenerative properties secondary to paracrine secretion of various molecules in response to environmental stimulation.
T6 1037-1217 Sentence denotes We hypothesized that PLX-PAD cells would reduce the associated inflammation and tissue damage and lower blood pressure in mice with preeclampsia induced by TLR3 or TLR7 activation.
T7 1218-1382 Sentence denotes Injection of PLX-PAD cells on gestational day 14 significantly decreased systolic blood pressure by day 17 in TLR3-induced and TLR7-induced hypertensive mice (TLR3:
T8 1383-1408 Sentence denotes 144 to 111 mmHg and TLR7:
T9 1409-1515 Sentence denotes 145 to 106 mmHg; both p<0.05), and also normalized their elevated urinary protein/creatinine ratios (TLR3:
T10 1516-1538 Sentence denotes 5.68 to 3.72 and TLR7:
T11 1539-1566 Sentence denotes 5.57 to 3.84; both p<0.05).
T12 1567-1765 Sentence denotes Gestational day 17 aortic endothelium-dependent relaxation responses improved significantly in TLR3-induced and TLR7-induced hypertensive mice who received PLX-PAD cells on gestational day 14 (TLR3:
T13 1766-1785 Sentence denotes 35 to 65% and TLR7:
T14 1786-1810 Sentence denotes 37 to 63%; both p<0.05).
T15 1811-1978 Sentence denotes Additionally, markers of systemic inflammation and placental injury, increased markedly in both groups of TLR-induced hypertensive mice, were reduced by PLX-PAD cells.
T16 1979-2089 Sentence denotes Importantly, PLX-PAD cell therapy had no effects on these measures in pregnant control mice or on the fetuses.
T17 2090-2266 Sentence denotes These data demonstrate that PLX-PAD cell therapy can safely reverse preeclampsia-like features during pregnancy and have a potential therapeutic role in preeclampsia treatment.

Preeclampsia

Id Subject Object Predicate Lexical cue
PD-Preeclampsia-B_T1 128-140 ORPHA:275555 denotes Preeclampsia
PD-Preeclampsia-B_T2 349-361 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T3 402-414 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T4 690-702 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T5 1169-1181 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T6 2158-2170 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T7 2243-2255 ORPHA:275555 denotes preeclampsia

Preeclampsia-compare

Id Subject Object Predicate Lexical cue
PD-Preeclampsia-B_T1 128-140 ORPHA:275555 denotes Preeclampsia
PD-Preeclampsia-B_T2 349-361 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T3 402-414 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T4 690-702 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T5 1169-1181 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T6 2158-2170 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T7 2243-2255 ORPHA:275555 denotes preeclampsia

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 6-14 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
PD-UBERON-AE-B_T2 794-802 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
PD-UBERON-AE-B_T3 82-87 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T4 1141-1146 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T5 1300-1305 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T6 197-202 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ
PD-UBERON-AE-B_T7 465-478 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
PD-UBERON-AE-B_T8 728-731 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T9 1062-1065 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T10 1235-1238 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T11 1727-1730 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T12 1968-1971 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T13 1996-1999 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T14 2122-2125 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T15 812-823 http://purl.obolibrary.org/obo/UBERON_0003104 denotes mesenchymal
PD-UBERON-AE-B_T16 1117-1123 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T17 1593-1604 http://purl.obolibrary.org/obo/UBERON_0001986 denotes endothelium

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 197-202 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ
PD-UBERON-AE-B_T2 6-14 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
PD-UBERON-AE-B_T3 60-69 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placental
PD-UBERON-AE-B_T4 794-802 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
PD-UBERON-AE-B_T5 1862-1871 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placental
PD-UBERON-AE-B_T6 1117-1123 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue
PD-UBERON-AE-B_T7 82-87 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T8 1141-1146 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T9 1300-1305 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T10 465-478 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
PD-UBERON-AE-B_T11 728-731 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T12 1062-1065 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T13 1235-1238 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T14 1727-1730 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T15 1968-1971 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T16 1996-1999 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T17 2122-2125 http://purl.obolibrary.org/obo/UBERON_2001977 denotes PAD
PD-UBERON-AE-B_T18 812-823 http://purl.obolibrary.org/obo/UBERON_0003104 denotes mesenchymal
PD-UBERON-AE-B_T19 1593-1604 http://purl.obolibrary.org/obo/UBERON_0001986 denotes endothelium